Publications

Some of the articles we have published in the area of rational therapeutics

1. McCormack JP, Rangno RE. An evaluation and critique of the use of lipid-lowering drugs in a population base of 400,000 patients over the age of 65. Can J Clin Pharmacol 1994;1(1):27-32

2. McCormack JP, Rangno RE. Cholesterol lowering in the elderly Can J Clin Pharmacol 1994;1(2):51-2 (Letter)

3. McCormack JP, Rangno RE. Cholesterol lowering in the elderly Can J Clin Pharmacol 1994;1(3):99-100 (Letter)

4. McCormack JP, Rangno RE. Dose Titration: Minimize to Maximize. Therapeutics Letter (www.ti.ubc.ca). October 1995;10:1-2

5. McCormack JP, Rangno RE, Wright J. Evidence Based Drug Therapy: What Do the Numbers Mean? Therapeutics Letter (www.ti.ubc.ca). August/September/October 1996;15:1-4

6. McCormack JP, Levine M, Rangno RE. Primary prevention of heart disease and stroke: a simplified approach to estimating risk of events and making drug treatment decisions. Can Med Assoc J 1997;157:422-8

7. McCormack JP, Cooper, J. Carleton B. Simple approach to dosage adjustment in patients with renal disease. Amer J Health Syst Pharm 1997;54:2505-9

8. Bass F, McCormack JP. Effective clinical tobacco intervention. Therapeutics Letter. (www.ti.ubc.ca). September -October 1997;21:1-4

9. McCormack JP, Carleton B. A simpler approach to pharmacokinetic dosage adjustments. Pharmacotherapy 1997;17:1349-51

10. McCormack JP, Loewen P. Treatment of acute migraine headaches. Therapeutics Letter. (www.ti.ubc.ca). November-December 1997;22:1-4

11. McCormack JP, Levine M, Rangno RE. Patients offered treatment for CHD need full information to make decision. BMJ 1998; 316: 1021-2 (Letter)

12. Maclure M, Dormuth C, Naumann T, McCormack J, Rangno R, Whiteside C, Wright JM. Influences of educational interventions and adverse news about calcium channel blockers on first-line prescribing of antihypertensive drugs to elderly people in British Columbia. Lancet 1998; 352: 943?48

13. McCormack JP, Bassett K. The evidence for insulin lispro. Can Med Assoc J. 1998;159:1353 (Letter)

14. McCormack JP, Levine M, Rangno RE. An easier approach to estimating risk of coronary heart disease and stroke. Circulation 1999;99:2219 (Letter)

15. McCormack JP, Bassett K. The evidence for insulin lispro. Letter to the Editor. Can Med Assoc J. 1999;160:1551 (Letter)

16. McCormack JP, Bassett K. Celecoxib (Celebrex^®) Is it a Breakthrough Drug? Therapeutics Letter. (www.ti.ubc.ca) August-September 1999;31:1-2

17. Scheepers LD, Montgomery CJ, Kinahan AM, Dunn GS, Bourne RA, McCormack JP Plasma concentration of flumazenil following intranasal administration in children. Can J Anaesth. 2000;47(2):120-4

18. McCormack JP, Greenhalgh T. Seeing what you want to see in randomised controlled trials: versions and perversions of UKPDS data. BMJ 2000;320:1720-3

19. McCormack JP, Greenhalgh T. Seeing what you want to see in randomised controlled trials – Author’s reply. BMJ 2000;321:1078 (Letter)

20. McCormack JP. An emotional-based medicine approach to monitoring once-daily aminoglycosides. Pharmacotherapy. 2000;20:1524-7

21. McCormack JP, Greenhalgh T. Seeing what you want to see in randomised controlled trials: versions and perversions of UKPDS data. WJM 2001; 174:123-127 (a slightly adapted version of above BMJ article)

22. McCormack JP. Absolute vs. relative numbers in evaluating drug therapy. Amer Fam Physician, 2001;63:1913 (Letter)

23. McCormack JP. Generic vs. brand name drugs: The warfarin debate is wearing thin. J Inform Pharmacother 2001: 6 (Invited editorial)

24. McGrath AM, Gardner DM, McCormack J. Is home peak expiratory flow monitoring effective for controlling asthma symptoms? J Clin Pharm Ther 2001; 26:311-317

25. Nair K, Dolovich L, Cassels A, McCormack JP, Levine M, Gray J, Mann K, Burns S. What patients want to know about their medications. Focus group study of patient and clinician perspectives. Can Fam Physician 2002;48:104-10

26. McCormack J, Perry T, Rangno R, van Breemen C, Wright JM Assessing the quality of clinical practice guidelines Can Med Assoc J 2002;166:168 (letter)

27. McCormack JP, Rangno RE Digging for data from the cox-2 trials. Can Med Assoc J;166:1649-50, 2002

28. McCormack JP. ALLHAT – so what. J Informed Pharmacotherapy 2003;12:1

29. Cassels A, Hughes MA, Cole C, Mintzes B, Lexchin J, McCormack JP. Drugs in the news: How well do Canadian Newspapers report the good, the bad and the ugly of new drugs. Can Med Assoc J 2003;168:1133-7

30. McCormack JP, Dolovich L, Levine M, Burns S, Nair K, Cassels A. Mann K, Gray J. Providing evidence-based information to patients in general practice and pharmacies: What is the acceptability, usefulness and impact on drug use? Health Expectations 2003:6:281-9

31. McCormack J, Loewen P, Jewesson P. Why is There No Value in Clinical Practice Guidelines? J Informed Pharmacotherapy 2003;14

32. Virani A. Drug Daze. How to prevent or manage drug induced cognitive Impairment. Pharmacy Practice. 2003;19:35-47

33. Carrey N, Virani A. Suicidal ideation reports from pediatric trials for paroxetine and venlafaxine. The Canadian Child Psychiatry Review 2003;12:101-102

34. Virani A, Crown N. The Impact of a Clinical Pharmacist on Patient and Economic Outcomes in a Child and Adolescent Mental Health Unit. CJHP 2003;56:158-62.

35. Bauer G, Virani A, Pohar R. Pharmacists get in the depression management loop. Pharmacy Practice 2003;19:D15-17.

36. Virani A. ADHD: What’s all the Hype? A workbook for pharmacists. Toronto, ON: Apotex 2003.

37. Virani A. The pharmacists guide to psychiatric disorders in children and adolescents: A continuing education article for pharmacists. Virtual Learning 2003.

38. Virani A. Evaluating the Pharmacological Treatment of Depression. Psychiatric Times (Suppl.) 2004;(Jul):1-8.

39. Virani A. Are Antidepressants Safe and Effective in Pediatric Patients? Child and Adolescent Psychiatric Newsletter. 2004;(Jul):1-7.

41. McCormack J, Loewen P, Jewesson P.  Dissemination of results needs to be tracked as well as the funding is. (letter)BMJ 2005;331:456

42. McCormack JP, Johns K, Tildesley H. Metformin’s contraindications be contraindicated? CMAJ 2005:173:503-4

43. Virani A. Psychopharmacology Update: Spotlight on Atomoxetine. J Can Acad Child Adolesc Psychiatry. 2005 (14);4:96-8

44. Virani A. Antidepressants and Suicide in Youth: Weighing the Evidence. Pharmacy Practice. 2005;21(2):30-36

45. McCormack J. Loewen P. The other side of the bezafibrate infarction prevention trial data.[Comment. Letter] Arch Intern Med. 2005;165:2431-2

46. Dolovich L, Burns S, Cassels A, Levine M, Nair K, McCormack JP, Mann K, Gray J. Using patient-oriented evidence-based information guides in practice: The family physician and community pharmacist perspective. Drug Information Journal. 2006;40:61-67

47. Elan C Paluck EC, McCormack JP, Ensom MHH, Levine M, Soon JA, Fielding DW. Outcomes of bupropion therapy for smoking cessation during routine clinical use. Ann Pharmacother 2006;40: 185-90

48. Pidsosny I, Virani A. Pediatric Psychopharmacology Update: Psychostimulants and Tics – Past, Present and Future. J Can Acad Child Adolesc Psychiatry. 2006;15(2):84-6

49. McCormack JP, Loewen P. Adding “value” to clinical practice guidelines. Can Fam Physician 2007;53:1327-35

50. McCormack JP. Do ß-blockers have a role in treating hypertension?: NO Can Fam Physician 2007;53:614-7

51. Wright J, McCormack JP. Mild Hypertension – An approach to using evidence in the decision making process. Therapeutics Letter. (www.ti.ubc.ca) 2007;62:1-2

52. McCormack JP, Wright J. Using Framingham for primary prevention cardiovascular risk assessmentTherapeutics Letter. (www.ti.ubc.ca) 2007 63:1-2

53. Jureidini J, Perry TL jr, Virani A, Mintzes B, Wright JM. What is the evidence for using CNS Stimulants to treat ADHD in Children. (www.ti.ubc.ca) 2008;69:1-2

Books/chapter we have published in the area of rational therapeutics

1. Editor: Gray J. Associate Editors: Gillis A, Johnson G, Johnson J, MacLeod S, Matsui D, McCormack J, Patterson C, Rangno R, Richardson J. Therapeutic Choices – 1st to 4th edition. Canadian Pharmaceutical Association

2. Editor: McCormack JP. Associate Editors: Brown G, Rangno R, Levine M, Ruedy J. Drug Therapy Decision Making Guide.Philadelphia:WB Saunders 1996 (550 pages)

3. Virani AS. ADHD, in Therapeutics Choices, Fifth Edition. Canadian Pharmacists Association Publishers, 2007.

4. Bezchlibnyk-Butler K, Virani AS. Clinical handbook of psychotropic drugs for children and adolescents, Second Edition. Cambridge, MA: Hogrefe & Huber Publishers, 2004 and 2007. (346 pp) http://www.hhpub.com/index.html (ISBN 978-0-88937-309-9)